C4 Therapeutics (CCCC) – Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of C4 Therapeutics (NASDAQ: CCCC) recently:

• 2/28/2026 – C4 Therapeutics was upgraded by Wall Street Zen from “strong sell” to “hold”.
• 2/26/2026 – C4 Therapeutics had its price target raised by Barclays PLC from $5.00 to $7.00. They now have an “overweight” rating on the stock.
• 2/26/2026 – C4 Therapeutics had its “buy” rating reaffirmed by TD Cowen.
• 2/23/2026 – C4 Therapeutics had its price target raised by Brookline Capital Acquisition Corp. from $20.00 to $30.00. They now have a “buy” rating on the stock.
• 1/21/2026 – C4 Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.

C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degraders. Utilizing its proprietary Controlled Inducible Degradation (CiD) platform, the company seeks to eliminate disease-causing proteins by harnessing the body’s natural protein disposal machinery. This approach aims to address a wide range of oncology and immuno-oncology indications by targeting proteins that have historically been difficult to inhibit with traditional small molecules or antibodies.

The company’s pipeline includes multiple small-molecule degrader candidates advancing through preclinical and clinical stages.